List of Excipients in Branded Drug HEPARIN SODIUM IN DEXTROSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	HEPARIN SODIUM IN DEXTROSE	heparin sodium and dextrose	0264-9567	ANHYDROUS CITRIC ACID
B Braun Medical Inc	HEPARIN SODIUM IN DEXTROSE	heparin sodium and dextrose	0264-9567	SODIUM METABISULFITE
B Braun Medical Inc	HEPARIN SODIUM IN DEXTROSE	heparin sodium and dextrose	0264-9567	SODIUM PHOSPHATE, DIBASIC
B Braun Medical Inc	HEPARIN SODIUM IN DEXTROSE	heparin sodium and dextrose	0264-9567	WATER

Heparin Sodium in Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 30, 2026

Heparin sodium in dextrose is a mature injectable platform whose commercial value comes from ready-to-administer delivery, hospital workflow savings, supply reliability, and container performance rather than from novel active-ingredient chemistry. The strongest opportunities are premixed IV bags, standardized concentrations, low-sorption materials, barcode-enabled packaging, and supply contracts. Dextrose is generally a functional vehicle, not a source of meaningful exclusivity.

What is heparin sodium in dextrose?

Heparin sodium in dextrose is an intravenous solution containing unfractionated heparin sodium in a dextrose solution, commonly 5% dextrose in water. It is used for anticoagulation and prevention or treatment of thromboembolic conditions when intravenous administration is appropriate.

Attribute	Commercial profile
Active ingredient	Heparin sodium, unfractionated heparin
Source	Predominantly porcine intestinal mucosa
Dosage form	Sterile intravenous solution
Typical vehicle	Dextrose in water, commonly 5%
Administration	Intravenous infusion or institutional protocol-based use
Preservative profile	Usually preservative-free for large-volume parenteral use
Primary customers	Hospitals, integrated delivery networks, wholesalers, government purchasers
Regulatory pathway	Drug approval or abbreviated approval depending on product and sponsor
Biosimilar pathway	Generally not the principal competitive pathway
Main substitutes	Heparin sodium in sodium chloride, unfractionated heparin vials, low-molecular-weight heparins, direct oral anticoagulants in appropriate indications

The product must maintain heparin potency, sterility, container integrity, and acceptable compatibility throughout its labeled shelf life. Product labeling typically includes warnings for hemorrhage, heparin-induced thrombocytopenia, medication errors, and variability in patient response. [1]

What excipients are used in heparin sodium in dextrose?

The core excipient system is deliberately simple. A typical formulation contains dextrose, water for injection, and pH-adjusting agents when necessary. The formulation is usually free of antimicrobial preservatives because the product is packaged for single use or aseptic hospital administration.

Component	Function	Strategic relevance
Dextrose	Isotonicity adjustment and aqueous vehicle	Supports physiologic osmolality and differentiates the product from saline presentations
Water for injection	Solvent	Must meet compendial quality requirements
Sodium hydroxide or hydrochloric acid	pH adjustment	Supports stability and batch consistency
Container-contact materials	Primary packaging system	Can affect adsorption, extractables, leachables, and shelf life

Dextrose concentration is not merely a label attribute. It affects osmolality, infusion-site tolerance, compatibility with concurrent fluids, and suitability for patients for whom glucose load matters. In a hospital setting, a dextrose-based carrier can be clinically useful but may be less desirable than sodium chloride for patients with hyperglycemia, insulin dependence, or fluid-management constraints.

Why is dextrose a commercially relevant excipient?

Dextrose creates a product-selection distinction without requiring a new active ingredient. Hospitals often maintain both heparin-in-dextrose and heparin-in-saline presentations to align with patient-specific fluid requirements and institutional protocols.

Commercial advantages include:

• Ready-to-use administration without bedside dilution.
• Lower preparation burden for pharmacy and nursing staff.
• Reduced calculation and compounding risk.
• Standardized concentrations for infusion pumps.
• Compatibility with hospital purchasing formularies.
• Potential reduction in manipulation-related contamination risk.

The disadvantages include glucose exposure, potential incompatibility with some co-infused drugs, and a narrower patient fit than a saline-based presentation.

What formulation strategy is strongest for heparin sodium in dextrose?

The strongest formulation strategy is not excipient novelty. It is control of stability, potency, packaging, and usability.

Concentration architecture

A sponsor should offer a limited, protocol-aligned concentration portfolio rather than a large number of variants. Too many strengths increase inventory complexity and medication-selection risk. A practical portfolio can include:

1. A lower-concentration bag for routine infusion protocols.
2. A higher-concentration bag for fluid-restricted patients.
3. A compact presentation for emergency or intensive-care use.

The exact strengths must correspond to FDA-approved labeling, institutional protocols, and infusion-pump libraries. Concentration rationalization is important because heparin errors can produce severe bleeding or inadequate anticoagulation.

pH and chemical stability

Heparin is a highly charged polysaccharide mixture. Stability can be affected by pH, ionic environment, temperature, agitation, light exposure, and interaction with container surfaces. A commercial formulation should establish:

• Potency retention over the full shelf life.
• Absence of visible particles and unacceptable color change.
• Container-closure integrity.
• Compatibility with the labeled administration set.
• Resistance to adsorption or loss at low concentrations.
• Stability after handling under expected hospital conditions.

The label should define storage conditions and any restrictions on freezing, excessive heat, or prolonged exposure outside controlled storage. [1]

Container and delivery-system selection

The primary container is a major source of differentiation. Flexible polyolefin bags, multilayer bags, and other parenteral systems can produce different extractables, leachables, oxygen transmission, and adsorption profiles.

Key development variables include:

• Heparin recovery after storage in the final container.
• Potency at the beginning and end of shelf life.
• Interaction with tubing and infusion sets.
• Port design and needle-free access.
• Bag collapse behavior during infusion.
• Label readability under low-light clinical conditions.
• Tamper evidence and overwrap performance.

A bag that preserves potency but is difficult to connect or read can lose in hospital tenders to a technically similar product with better workflow design.

What patents protect heparin sodium in dextrose?

The mature product category is unlikely to be protected by a broad, durable composition-of-matter patent covering heparin sodium in dextrose. Heparin sodium and dextrose are established pharmaceutical materials, and premixed parenteral solutions have long commercial histories.

IP category	Likely position	Commercial impact
Heparin active ingredient	Historically mature	Limited blocking-patent value
Dextrose vehicle	Established excipient	Usually weak composition protection
Premixed solution	Potential formulation or process claims	May create narrow protection if technically specific
Container system	Potential patent activity	Can protect bag, ports, coatings, or multilayer structures
Manufacturing process	Possible process claims	Relevant where the process improves potency or stability
Labeling or method of use	Limited value for established indications	May affect generic labeling strategy
Device integration	Potentially meaningful	Can support hospital differentiation
Trade secrets	Important	Source control, testing, and release methods can be difficult to replicate

The relevant public patent questions are sponsor- and presentation-specific. A patent number or expiration date cannot be assigned reliably to the entire category because heparin sodium in dextrose is sold in multiple strengths, containers, and regulatory configurations.

The practical conclusion is that patent risk is usually lower than regulatory and supply-chain risk, but container and manufacturing patents can still affect a particular entrant. Patent review should examine:

• U.S. patent assignments for the named product sponsor.
• FDA Orange Book patent listings for the specific approved product.
• Patent claims covering flexible IV bags and administration ports.
• Process claims directed to heparin recovery, sterilization, or stability.
• Litigation involving the exact strength and container configuration.

The FDA Orange Book is the principal public source for listed patents and approved therapeutic-equivalence information. [2]

When does heparin sodium in dextrose lose exclusivity?

Heparin sodium in dextrose generally has no single category-wide exclusivity date. Exclusivity depends on the sponsor, product approval date, regulatory pathway, formulation, and any listed patents.

For many mature heparin products, the principal commercial barriers are:

• FDA approval and manufacturing validation.
• Sterile manufacturing capacity.
• Heparin raw-material qualification.
• Analytical testing.
• Facility inspection status.
• Product-specific labeling.
• Contracting and hospital adoption.

If a product is approved through an abbreviated application, generic competition may be possible once applicable regulatory requirements are met. If the product is an original or reformulated branded presentation, any remaining regulatory exclusivity and listed patent rights must be evaluated in the Orange Book.

What is the Orange Book status of heparin sodium in dextrose?

Orange Book status must be assessed at the application level. The category includes different sponsors and product configurations, so one Orange Book result does not establish the patent position for every heparin-in-dextrose product.

A product-level review should identify:

• Application number.
• Sponsor or applicant.
• Strength and package configuration.
• Therapeutic-equivalence rating.
• Listed patents, if any.
• Patent-use codes.
• Exclusivity codes and dates.
• Approved labeling.

A product with no listed patents can still have meaningful commercial protection through manufacturing complexity, hospital contracts, and supply reliability. [2]

Are Paragraph IV challenges relevant to heparin sodium in dextrose?

Paragraph IV litigation may arise when an abbreviated applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The relevance is product-specific.

For a mature heparin-in-dextrose product, Paragraph IV risk is typically narrower than for a recently approved small-molecule product because:

• The active ingredient is old.
• Broad composition claims are unlikely to remain enforceable.
• The main potential claims may concern formulation, container, process, or device features.
• Hospitals can often substitute among approved heparin presentations if clinically appropriate.

A Paragraph IV strategy would be most commercially relevant if a branded product has a listed patent covering a specific premix concentration, container, stability feature, or administration system. The entrant must also assess whether it can launch a formulation that avoids the patented claim while maintaining equivalent clinical and regulatory performance.

What manufacturing and intellectual-property barriers affect entry?

Heparin raw-material supply

Heparin is a complex animal-derived polysaccharide. Batch variability, source qualification, contamination controls, and supply concentration create barriers that do not arise to the same extent with simple synthetic excipients. The 2008 heparin contamination crisis led FDA and international regulators to intensify oversight of crude heparin supply, oversulfated contaminants, analytical characterization, and supplier controls. [3]

A new manufacturer needs:

• Qualified porcine heparin suppliers.
• Source and traceability controls.
• Identity and potency testing.
• Contaminant testing.
• Robust incoming-material specifications.
• Multiple-source or contingency planning where feasible.

Sterile manufacturing

Large-volume parenteral production requires validated aseptic processing or terminal sterilization where compatible with the formulation and container. The manufacturing process must control particulate matter, bioburden, endotoxin, fill volume, and container closure.

Sterile capacity is a meaningful barrier to entry because a product may have an attractive formulation but remain commercially nonviable without dependable fill-finish capacity.

Analytical methods

Heparin requires more than a single potency assay. A control strategy can include:

• Anti-factor Xa activity.
• Anti-factor IIa activity where applicable.
• Identification testing.
• Molecular or structural characterization.
• Bacterial endotoxin testing.
• Sterility testing.
• Particulate testing.
• Container compatibility and adsorption studies.

Analytical comparability is especially important for a heterogeneous biological polymer. The sponsor must demonstrate consistent anticoagulant activity and acceptable quality across lots.

What FDA regulatory status applies to heparin sodium in dextrose?

Heparin sodium in dextrose is regulated as a prescription sterile injectable drug. Approval depends on the product’s application pathway and the sponsor’s ability to demonstrate quality, safety, efficacy where required, and manufacturing compliance.

The principal regulatory issues are:

• Correct strength expression in units per volume.
• Accurate infusion instructions.
• Appropriate contraindications and warnings.
• Compatibility and storage labeling.
• Control of particulate and microbial contamination.
• Stability in the final container.
• Heparin-induced thrombocytopenia warnings.
• Medication-error mitigation.

The product is not generally treated as a conventional biosimilar opportunity. Heparin is a complex, animal-derived polysaccharide, and commercial competition is more closely tied to generic or follow-on drug approval, product quality, and presentation than to the standard monoclonal-antibody biosimilar model.

What commercial opportunities exist for heparin sodium in dextrose?

Ready-to-administer hospital products

The clearest opportunity is a ready-to-use bag that reduces pharmacy compounding and bedside dilution. Hospitals value standardized products that integrate with smart pumps, barcode medication administration, and electronic medication records.

Shortage-resilient supply

FDA’s drug-shortage database has periodically identified supply constraints involving injectable heparin products and related hospital anticoagulants. Availability, allocation management, and manufacturing redundancy can therefore be commercial differentiators. [4]

A supplier with validated secondary manufacturing or multiple fill-finish sites can compete on continuity of supply rather than price alone.

Contract manufacturing and private-label supply

The product is suitable for:

• Hospital group purchasing organization contracts.
• Government procurement.
• Private-label arrangements.
• Regional distributor supply.
• Portfolio bundling with saline-based heparin and other critical-care injectables.

The strongest partner profile is a company with sterile injectable capacity, established hospital distribution, and a compliant heparin supply chain.

Packaging and medication-safety differentiation

Commercially defensible improvements can include:

• High-contrast strength labeling.
• Distinctive bag geometry.
• Barcode placement compatible with automated scanning.
• Small-volume and fluid-restricted presentations.
• Tamper-evident ports.
• Clearly separated heparin concentration and total bag volume.
• Improved overwrap and storage handling.
• Smart-pump library integration.

These improvements may not support broad patent exclusivity, but they can improve formulary adoption and tender performance.

How does heparin sodium in dextrose compare with heparin sodium in saline?

Factor	Heparin in dextrose	Heparin in saline
Vehicle	Dextrose solution	Sodium chloride solution
Patient fit	Useful where dextrose carrier is acceptable	Often preferred where glucose exposure is undesirable
Fluid-management role	May be useful in selected protocols	Common option for routine electrolyte-based infusion
Commercial differentiation	Strong where institutions maintain dextrose protocols	Broad hospital familiarity
Formulation complexity	Generally low	Generally low
Main drawback	Glucose load and patient-specific restrictions	Sodium and chloride load
Substitution	Depends on labeling, protocol, and clinical judgment	Depends on labeling, protocol, and clinical judgment

The two presentations compete mainly on hospital protocol, patient mix, availability, and price. A sponsor that offers both can improve contracting leverage and reduce substitution to a rival supplier.

What generic launch risks exist?

A generic entrant faces moderate regulatory and high execution risk.

Risk	Impact
Heparin-source interruption	High
Sterile fill-finish failure	High
Potency or recovery loss in the container	High
FDA inspection observations	High
Labeling or concentration errors	High
Hospital tender exclusion	Moderate to high
Patent blocking rights	Product-specific
Price erosion	Moderate to high
Shortage-driven demand volatility	Moderate

A launch is most attractive when the entrant has dependable heparin sourcing, an established sterile manufacturing platform, and access to hospital purchasing channels. Price-only competition is less attractive because the product is mature and likely subject to contracting pressure.

What is the revenue exposure and competitive landscape?

Revenue exposure is concentrated in hospital and institutional channels. The product is less dependent on retail pharmacy than oral anticoagulants and therefore responds to hospital admissions, intensive-care utilization, cardiovascular procedures, oncology care, and anticoagulation protocols.

Competitive pressure comes from:

• Established injectable manufacturers.
• Generic heparin suppliers.
• Premixed IV product specialists.
• Hospital pharmacy compounders.
• Low-molecular-weight heparin manufacturers.
• Direct oral anticoagulant companies in clinically substitutable indications.

The highest-value commercial position is usually a reliable institutional supplier with a broad injectable portfolio. Heparin in dextrose alone may be a low-margin product, but it can increase the value of a broader hospital-contract offering.

Key Takeaways

• Heparin sodium in dextrose is a mature sterile injectable product with limited broad composition-patent potential.
• Dextrose is a functional excipient that supports a distinct hospital presentation but does not normally create durable exclusivity.
• Container compatibility, heparin recovery, sterility, and supply-chain controls are the main technical barriers.
• The most credible commercial opportunities are ready-to-use bags, standardized concentrations, shortage-resilient supply, and safety-oriented packaging.
• Paragraph IV risk and Orange Book exposure must be evaluated for the specific sponsor, application, strength, and container.
• Heparin is not primarily a biosimilar opportunity; competition is more closely tied to generic or follow-on sterile-drug approval.
• The strongest market position comes from pairing heparin in dextrose with saline-based heparin and other critical-care injectables.

FAQs

Is dextrose in heparin sodium injection a novel excipient strategy?

No. Dextrose is an established parenteral vehicle and tonicity agent. Its strategic value is product positioning, patient selection, and hospital protocol alignment rather than novel chemistry.

Can a manufacturer patent a heparin-in-dextrose IV bag?

A manufacturer may obtain narrow patents covering a specific formulation, container, port, stability improvement, process, or integrated delivery system. Broad protection over heparin sodium dissolved in dextrose is less likely for a mature product category.

Does heparin sodium in dextrose require a biosimilar application?

Generally no. Commercial entry is typically evaluated under the applicable drug approval framework rather than the standard biosimilar pathway used for therapeutic proteins.

Which container material is best for heparin in dextrose?

The best material is the one that maintains potency, limits adsorption and leachables, preserves container integrity, and supports reliable clinical use through the full labeled shelf life. Final selection requires product-specific stability and compatibility testing.

Is heparin in dextrose commercially stronger than heparin in saline?

Not universally. Dextrose provides differentiation, but saline may have broader routine use. Commercial strength depends on hospital protocols, patient mix, supply reliability, pricing, and whether the supplier offers both presentations.

References

1. DailyMed. (n.d.). Heparin sodium in 5% dextrose injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/information-drug-class/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2008). FDA heparin update: Contamination and safety information. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/